Genetic Polymorphism Of Cytochrome P450 -2d6*4 In Cannabis Smokers

10.5580/1a2c ◽  
2008 ◽  
Vol 5 (1) ◽  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

Genetic Polymorphism of Cytochrome P450 2D6*4 and 2D6*5 in an Adult Population Sample from Costa Rica

2016 ◽  
Vol 16 (1-2) ◽  
pp. 10-15
Author(s):  
Chaverri-Fernández José Miguel ◽  
Ortiz-Ureña Angie ◽  
Díaz-Madriz José Pablo ◽  
Alvarado-Leitón Jeimy ◽  
García-Chaves, Sergio ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Costa Rica ◽  
Adult Population ◽  
Population Sample ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

scholarly journals Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women?

2021 ◽  
Vol 12 ◽  
Author(s):  
Camille Robin ◽  
Benjamin Hennart ◽  
Franck Broly ◽  
Philippine Gruchala ◽  
Geoffroy Robin ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Clinical Response ◽  
Cytochromes P450 ◽  
Clomiphene Citrate ◽  
Weighted Kappa ◽  
Ovarian Response ◽  
Kappa Coefficient ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

IntroductionCytochrome P450 2D6, 3A4 and 3A5 are involved in the metabolism of many drugs. These enzymes have a genetic polymorphism responsible for different metabolic phenotypes. They play a role in the metabolism of clomiphene citrate (CC), which is used to induce ovulation. Response to CC treatment is variable, and no predictive factors have thus far been identified.ObjectiveTo study a possible link between the cytochrome P450 2D6, 3A4 and 3A5 polymorphisms and clinical response to CC.Study DesignSeventy-seven women with anovulatory Polycystic Ovarian Syndrome (PCOS) treated with CC were included which determined their cytochrome P450 2D6, 3A4 and 3A5 genotypes and used the results to predict ovarian response to this drug. Predicted responses based on the cytochrome genotypes were compared with the observed clinical responses using the calculation of a weighted Kappa coefficient.Main Outcome MeasuresNumber of dominant follicles assessed by ultrasound at the end of the follicular phase and confirmation of ovulation by blood progesterone assay in the luteal phase.ResultsConcordance between the predicted and observed responses for the combination of the three cytochromes was 36.71%, with a negative Kappa coefficient (K = -0.0240), which corresponds to a major disagreement. Similarly, for predictions based on the cytochrome P450 2D6 genotype alone, only 39.24% of predictions were verified (coefficient K = -0.0609).ConclusionThe genetic polymorphism of cytochromes P450 2D6, 3A4 and 3A5 does not appear to influence clinical response to CC used to induce ovulation in anovulatory PCOS women.

scholarly journals Breast cancer: Role of pharmacogenetics in tamoxifen therapy

2016 ◽  
Vol 1 (1) ◽  
pp. 10
Author(s):  
Smriti Mishra ◽  
Manish Manish
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Clinical Outcome ◽  
Tamoxifen Therapy ◽  
Uridine Diphosphate ◽  
Cytochrome P450 2D6 ◽  
Cytochrome P450 3A ◽  
P450 2D6

<p><span>The role of pharmacogenetics in the personalization of tamoxifen therapy has relevance in the management of breast cancer. Since Tamoxifen is a pro-drug, genetic polymorphism in Phase I and Phase II drug metabolizing enzymes involved in the bioconversion of tamoxifen to therapeutically active metabolites is critical in determining therapeutic efficacy and adverse drug reactions of the therapy in breast cancer patients. In this review, the role of pharmacogenetics in the personalization of tamoxifen therapy has been discussed. Since, metabolism of tamoxifen by Cytochrome P450 2D6 is significant in determining the therapeutic efficacy of the drug, most of the clinical evidence on tamoxifen pharmacogenetics have been correlated with cytochrome p450 2D6 genetic polymorphism. However, there is discordance in the clinical data, and one of the reasons is the incomplete analysis of all the alleles of cytochrome p450 2D6. International Tamoxifen Pharmacogenomics Consortium has been formed to assess   the discordance. There are also clinical evidences associating genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome of tamoxifen therapy. However, associations of genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome in populations of different ethnicity are unexplored. Evidences on  the association of genetic polymorphisms and the clinical outcome have been summarized in the Table.  Since cost, statistically significant sample population size, labor and ethical issues are the major concerns of a pharmacogenetic investigation; the significance of bottom-up approach in pharmacogenetics has been discussed.</span></p>

scholarly journals Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro

2016 ◽  
pp. 1909 ◽  
Author(s):  
Zhe Wang ◽  
Li Wang ◽  
Ren-ai Xu ◽  
Yun-yun Zhan ◽  
Cheng-ke Huang ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Cytochrome P450 2D6 ◽  
P450 2D6
Sign in / Sign up

Export Citation Format

Share Document